Amyloid precursor proteins protect neurons of transgenic mice against acute and chronic excitotoxic injuries in vivo.
The beta-amyloid protein precursor (APP) is well conserved across different species and may fulfill important physiological functions within the CNS. While high-level neuronal expression of amyloidogenic forms of human APP results in beta-amyloid production and neurodegeneration, lower levels of neuronal human APP expression in neurons of transgenic mice may primarily accentuate physiological functions of this molecule. To assess the neuroprotective potential of human APP in vivo, mice from seven distinct transgenic lines expressing different human APP isoforms from the neuron-specific enolase promoter were challenged with systemic kainate injections (n=30) or transgene-mediated glial expression of gp120 (n=32), an HIV-1 protein capable of inducing excitotoxic neuronal damage. To quantitate human APP-mediated neuroprotection. the area of neuropil occupied by presynaptic terminals and neuronal dendrites in the neocortex and hippocampus of each mouse was determined using laser scanning confocal microscopy of double-immunolabelled brain sections and computer-aided image analysis. Compared with gp120 singly transgenic controls, mice from three of three human APP751gp120 bigenic lines expressing the 751 amino acid form of human APP at low levels showed significant protection against degeneration of presynaptic terminals; two of these lines also showed significantly less damage to neuronal dendrites. Two of three human APP695/gp120 bigenic lines expressing human APP695 at low levels were protected against presynaptic and dendritic damage, whereas one low expressor line and a human APP695/gp120 bigenic line expressing human APP695 at higher levels showed no significant protection. In the corresponding human APP singly transgenic lines, overexpressing only specific human APP isoforms, significant protection against kainate-induced degeneration of presynaptic terminals and neuronal dendrites was found in two of three human APP751 lines and not in any of the four human APP695 lines tested. These results indicate that human APP can protect neurons against chronic and acute excitotoxic insults in vivo and that human APP isoforms differ in their neuroprotective potential, at least with respect to specific forms of neural injury. It is therefore possible that impairments of neuroprotective human APP functions or aberrant shifts in human APP isoform ratios could contribute to neurodegeneration.
Masliah
E
E
Department of Neurosciences, University of California at San Diego, La Jolla 92093-0624, U.S.A.
Westland
C E
CE
Rockenstein
E M
EM
Abraham
C R
CR
Mallory
M
M
Veinberg
I
I
Sheldon
E
E
Mucke
L
L
D016564:Amyloid beta-Protein Precursor / Q000494:pharmacology*; D000818:Animals; D001921:Brain / Q000473:pathology; D018690:Excitatory Amino Acid Agonists / Q000633:toxicity; D015870:Gene Expression / Q000187:drug effects; D005911:Gliosis / Q000473:pathology; D015699:HIV Envelope Protein gp120 / Q000633:toxicity; D006801:Humans; D007608:Kainic Acid / Q000633:toxicity; D051379:Mice; D008810:Mice, Inbred C57BL; D008822:Mice, Transgenic; D009410:Nerve Degeneration / Q000187:drug effects; D009474:Neurons / Q000187:drug effects*; D009498:Neurotoxins / Q000037:antagonists & inhibitors* / Q000633:toxicity; D012333:RNA, Messenger / Q000032:analysis / Q000096:biosynthesis; D019076:Transgenes
D016564:Amyloid beta-Protein Precursor; D018690:Excitatory Amino Acid Agonists; D015699:HIV Envelope Protein gp120; D009498:Neurotoxins; D012333:RNA, Messenger; D007608:Kainic Acid